Five Prime Therapeutics Inc., a company focused on immuno-oncology therapeutics, has appointed its chief operating officer (COO) Aron Knickerbocker as CEO and president – effective Jan. 1, 2017. Knickerbocker will succeed Lewis T. Williams, the current president, CEO and chair of the board, who will continue as executive chair of the board. Knickerbocker joined the company in 2009 and before his position as COO, he was executive vice president and chief business officer.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.